Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel

Rixe, Olivier; Ortuzar, Waldo Feliu; Álvarez, Manuel; Parker, Ricardo J.; Reed, Eddie; Paull, K.; Fojo, Tito

doi:10.1016/s0006-2952(97)81490-6

Cited by 539 publications

(344 citation statements)

References 25 publications

Supporting

Mentioning

322

Contrasting

Unclassified

Order By: Relevance

“…Thus, both drugs show very similar cytotoxicity profiles. Oxaliplatin exhibited a unique cytotoxicity profile compared to that of cisplatin and carboplatin, which is consistent to that observed by others (Burchenal et al, 1980;Rixe et al, 1996). We also examined the sensitivity of the cell lines to AMD473, a platinum complex that has been shown previously to circumvent the acquired cisplatin resistance phenotypes in some in vitro models (Raynaud et al, 1997).…”

Section: Discussionsupporting

confidence: 80%

See 1 more Smart Citation

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells

et al. 2005

View full text Add to dashboard Cite

Platinum-based chemotherapeutic regimens are ultimately unsuccessful due to intrinsic or acquired drug resistance. Understanding the molecular basis for platinum drug sensitivity/resistance is necessary for the development of new drugs and therapeutic regimens. In an effort to identify such determinants, we evaluated the expression of approximately 4000 genes using cDNA microarray screening in a panel of 14 unrelated human ovarian cancer cell lines derived from patients who were either untreated or treated with platinum-based chemotherapy. These data were analysed relative to the sensitivities of the cells to four platinum drugs (cisdiamminedichloroplatinum (cisplatin), carboplatin, DACH-(oxalato)platinum (II) (oxaliplatin) and cis-diamminedichloro (2-methylpyridine) platinum (II) (AMD473)) as well as the proliferation rate of the cells. Correlation analysis of the microarray data with respect to drug sensitivity and resistance revealed a significant association of Stat1 expression with decreased sensitivity to cisplatin (r ¼ 0.65) and AMD473 (r ¼ 0.76). These results were confirmed by quantitative RT -PCR and Western blot analyses. To study the functional significance of these findings, the full-length Stat1 cDNA was transfected into drug-sensitive A2780 human ovarian cancer cells. The resulting clones that exhibited increased Stat1 expression were three-to five-fold resistant to cisplatin and AMD473 as compared to the parental cells. The effect of inhibiting Jak/Stat signalling on platinum drug sensitivity was investigated using the Janus kinase inhibitor, AG490. Pretreatment of platinum-resistant cells with AG490 resulted in significant increased sensitivity to AMD473, but not to cisplatin or oxaliplatin. Overall, the results indicate that cDNA microarray analysis may be used successfully to identify determinants of drug sensitivity/resistance and future functional studies of other candidate genes from this database may lead to an increased understanding of the drug resistance phenotype.

show abstract

Section: Discussionsupporting

confidence: 80%

“…The DACH platinum compounds are a series of complexes containing a diaminocyclohexane carrier ligand (Connors et al, 1972;Kidani et al, 1976;Rixe et al, 1996). These compounds have a unique cytotoxicity profile as compared to cisplatin and exhibit collateral sensitivity in some cisplatin-resistant cell lines (Burchenal et al, 1980).…”

mentioning

confidence: 99%

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells

et al. 2005

View full text Add to dashboard Cite

show abstract

“…After 1 h of drug incubation, the medium was replaced with fresh medium and cells were harvested 72 h later for counting with a cell counter. When 6 assaying cell sensitivity to 6-mercaptopurine (Sigma-Aldrich, Milan, Italy), treatment was for 72 h and cells were counted at the end of treatment. IC 50 is defined as the drug concentration producing 50% decrease of cell growth.…”

Section: Cell Lines and Cell Sensitivity To Drugsmentioning

confidence: 99%

“…Oxaliplatin has activity and a favorable pharmacological profile in epithelial ovarian cancer as well [5]. Oxaliplatin and cisplatin exhibit different sensitivity profiles indicating differences in drug-DNA interaction and/or cellular response or detoxification [6].…”

Section: Introductionmentioning

confidence: 99%

Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin

Beretta

Benedetti

Cossa

et al. 2010

Biochemical Pharmacology

103

View full text Add to dashboard Cite

show abstract

“…The National Cancer Institute's Anticancer Drug Screening Programme has shown oxaliplatin to have a very different profile from that of cisplatin when tested on colon cell lines with no crossresistance with cisplatin in most cell lines (Rixe et al, 1996). DNA adducts of oxaliplatin are not recognized by the DNA mismatch repair proteins.…”

mentioning

confidence: 99%

Oxaliplatin (L-OHP): a new reality in colorectal cancer

Bleiberg

1998

Br J Cancer

View full text Add to dashboard Cite

Summary Oxaliplatin (trans-/-diaminocyclohexane oxalatoplatinum; L-OHP) is a new platinum derivative for the treatment of advanced colorectal cancer. Preclinical data have shown that oxaliplatin is active in a wide range of human and murine tumour cell lines, and has been found to be non-cross-resistant with cisplatin in various cisplatin-resistant cell lines and tumours. Oxaliplatin in combination with 5-fluorouracil (5-FU) leads to synergistic antiproliferative activity both in vivo and in vitro. Clinical data have shown that oxaliplatin is active and well tolerated both as monotherapy and in combination with 5-FU/folinic acid in first-or second-line treatment of patients with metastatic colorectal cancer. Oxaliplatin has a very good safety profile, and studies have confirmed that peripheral sensory neuropathy is related to the cumulative dose of oxaliplatin administered and that this neuropathy is generally reversible after discontinuation of treatment. High response rates and prolonged survival have been achieved in metastatic colorectal cancer patients, even after 5-FU failure.Keywords: advanced colorectal cancer; first-line treatment; 5-fluorouracil/folinic acid; oxaliplatin; second-line treatment; synergistic antiproliferative activity Oxaliplatin (trans-/-diaminocyclohexane oxalatoplatinum; L-OHP) is a new platinum derivative in which oxalate is the hydrolysable ligand and diaminocyclohexane (DACH) the carrier ( Figure 1). The drug is the first clinically available platinum derivative that has been approved in France for the treatment of advanced colorectal cancer.Preclinical data have shown that oxaliplatin is active in a wide range of human and murine tumour cell lines (Silvestro et al, 1990). The National Cancer Institute's Anticancer Drug Screening Programme has shown oxaliplatin to have a very different profile from that of cisplatin when tested on colon cell lines with no crossresistance with cisplatin in most cell lines (Rixe et al, 1996). DNA adducts of oxaliplatin are not recognized by the DNA mismatch repair proteins. The combination of oxaliplatin with other drugs, such as 5-fluorouracil (5-FU) and CPT-I 1, can lead to synergistic antiproliferative activity in vivo and in vitro (Raymond et al, 1996.Five phase I studies have been carried out, involving 122 patients (Mathe et al, 1986;Caussanel et al, 1990;Extra et al, 1990). From these studies, it was clear that haematological toxicity was minimal, with no nephrotoxicity, ototoxicity or alopecia; the doselimiting toxicity was a peripheral sensory neuropathy that was related to the cumulative dose of oxaliplatin administered, and was generally reversible after treatment discontinuation. However, the toxicity profile of oxaliplatin will be discussed in more detail in the following paper. The maximal tolerated dose was 200 mg m-2, and the recommended dose for treating these patients in phase II studies was 130 mg m-2 every 3 weeks.Clinical data have shown that oxaliplatin is active and well tolerated, both as monotherapy and in combination with 5-...

show abstract

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel

Cited by 539 publications

References 25 publications

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells

Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin

Oxaliplatin (L-OHP): a new reality in colorectal cancer

Contact Info

Product

Resources

About